arrow
G

Giuseppe A. Palumbo

University of Catania
H指数:46
被引数:7,770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence

鲁索利替尼治疗失败后的骨髓纤维化患者:一种系统评价和合并分析,包括临床试验和真实世界证据中的III期疗效和综合安全性

2026-09-060
OAAI
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison

与最佳可用疗法相比,在既往接受过鲁索利替尼治疗的患者中,使用莫美洛替尼的总体生存率:一项匹配调整的间接比较

2026-02-210
OAAI
Plasma metabolomics and ctDNA analysis in newly diagnosed diffuse large B-cell lymphoma: an exploratory study

新诊断弥漫性大B细胞淋巴瘤的血浆代谢组学和ctDNA分析:一项探索性研究

2026-01-010
OAAI
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life Study

霍奇金炎症基础模型ME-IPS是一种在诊断时计算的新炎症基础预后模型:来自真实世界研究的结果

2025-11-010
PRE
Prothrombotic profiles in myelofibrosis: Fibrinogen oxidation and the beneficial effects of ruxolitinib

原发性骨髓纤维化中的促血栓形成表型:纤维蛋白原氧化及鲁索利尼布的益处

2025-10-180
OAAI
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database

基于EudraVigilance数据库的维生素K拮抗剂(VKAs)和新口服抗凝剂(NOACs)安全性比较

2025-10-180
OA
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib

修订后的“iRR6”模型在风险分层为1级的骨髓纤维化患者中使用鲁索利替尼治疗

Cancer
IF5.1
2025-08-210
OAAI
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma

[18F] fdg-pet影像组学与液体活检的整合可改善新诊断的弥漫性大b细胞淋巴瘤的预后预测

Leukemia
IF13.4
2025-07-080
OAAI
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea

真性红细胞增多症患者使用一线羟基脲治疗时,ELN临床体征和症状对血栓风险的影响

Leukemia
IF13.4
2025-05-280
OAAI
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
2025-01-200
OAAI